Lymphomas Clinical Trials

5 recruiting

Frequently Asked Questions

Common questions about Lymphomas clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 25 trials

Recruiting
Phase 1

Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV

Kaposi SarcomaViral Associated MalignanciesEBV/KSHV-associated Lymphomas
National Cancer Institute (NCI)58 enrolled1 locationNCT04902443
Recruiting

Specimen Collections From Participants With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and Cancer

LymphomasMulticentric Castleman s DiseaseHIV+2 more
National Cancer Institute (NCI)1,029 enrolled1 locationNCT00006518
Recruiting
Phase 1Phase 2

A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaAcute Leukemia+8 more
Ossium Health, Inc.12 enrolled9 locationsNCT05589896
Recruiting

Collection of Tissue Samples for Cancer Research

NeoplasmsMultiple MyelomaMyelodysplastic Syndrome+1 more
National Cancer Institute (NCI)5,000 enrolled17 locationsNCT00900198
Recruiting
Phase 1

A Study to Investigate Safety of INT2104 Infusions in Participants Aged 18 Years of Age and Older Who Have B-cell Cancers That Came Back After Previous Treatment

Precursor Cell Lymphoblastic Leukemia-LymphomaLymphomas Non-Hodgkin's B-Cell
Kite, A Gilead Company34 enrolled3 locationsNCT06539338
Recruiting
Phase 1

Study Evaluating Safety Pharmacokinetics and Pharmacodynamics of AUR112 in Patients With Relapsed Advanced Lymphoma

Relapsed Advanced Lymphomas
Aurigene Discovery Technologies Limited40 enrolled19 locationsNCT06755450
Recruiting
Phase 2

Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma

Lymphoproliferative DisordersImmune System DiseasesPeripheral T-cell Lymphomas
National Cancer Institute (NCI)330 enrolled2 locationsNCT03922724
Recruiting
Phase 2

Amping up With PemJAK

Non-Hodgkin LymphomaPeripheral T Cell LymphomaPrimary Mediastinal B Cell Lymphoma+5 more
Seda S. Tolu53 enrolled1 locationNCT07283822
Recruiting
Phase 1Phase 2

A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer

Locally AdvancedUnresectableMetastatic Cancers+1 more
Recursion Pharmaceuticals Inc.85 enrolled6 locationsNCT06678659
Recruiting
Phase 1

A Study of Ruxolitinib and Duvelisib in People With Lymphoma

T-cell Prolymphocytic LeukemiaT-cell LymphomasNK-Cell Lymphomas+1 more
Memorial Sloan Kettering Cancer Center70 enrolled9 locationsNCT05010005
Recruiting

Long-term Follow-up Study of Patients Receiving CAR-T Cells

Diffuse Large B Cell LymphomaChronic Lymphocytic LeukemiaMultiple Myeloma+6 more
Medical College of Wisconsin500 enrolled1 locationNCT03375619
Recruiting
Phase 1

A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas

LymphomasB-cell Lymphomas
M.D. Anderson Cancer Center33 enrolled1 locationNCT05773040
Recruiting

Local Registry of Primary Cutaneous T-cell Lymphomas

Primary Cutaneous T-cell Lymphomas NCT Number
Fondazione IRCCS Policlinico San Matteo di Pavia600 enrolled1 locationNCT07160023
Recruiting
Phase 1Phase 2

T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

High-grade B-cell LymphomaNon-Hodgkin LymphomaLymphoma+12 more
Estrella Biopharma, Inc.21 enrolled2 locationsNCT06343311
Recruiting
Not Applicable

Combating Cancer-Related Fatigue: A Personalized Supportive Care Program

Chronic Lymphocytic LeukemiaLymphomaFollicular Lymphoma+6 more
UNC Lineberger Comprehensive Cancer Center40 enrolled1 locationNCT06860880
Recruiting
Not Applicable

Interest of Individual Biomarkers From the Identification of Tumor Genotype by High-throughput Molecular Techniques

Lymphomas
Centre Hospitalier Universitaire Dijon1,200 enrolled1 locationNCT04417803
Recruiting
Phase 1

A Study of ATG-031 in Advanced Solid Tumors or B-cell Non-Hodgkin Lymphomas

Advanced Solid TumorsB-cell Non-Hodgkin Lymphomas
Antengene Biologics Limited80 enrolled4 locationsNCT06028373
Recruiting
Phase 2

Selinexor, High-dose Methotrexate, and Rituximab Combined With Radiotherapy for Newly Diagnosed, Transplant-ineligible Patients With Central Nervous System Lymphoma: An Open-label, Single-arm, Multicenter Phase II Study

Lymphomas
Second Affiliated Hospital of Soochow University26 enrolled1 locationNCT07002099
Recruiting
Phase 1Phase 2

A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)

Relapsed or Refractory T-cell Lymphomas
Bristol-Myers Squibb85 enrolled40 locationsNCT06035497
Recruiting
Phase 1

Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients With Relapsed or Refractory Lymphomas and Solid Tumors

Advanced Solid TumorRelapsed or Refractory Lymphomas
Lantern Pharma Inc.110 enrolled4 locationsNCT06132503